Why is Mangalam Drugs falling/rising?

As of 15-Sep, Mangalam Drugs and Organics Ltd is currently priced at 75.56, reflecting an increase of 0.56 or 0.75%. Despite this slight uptick, the stock has shown a significant decline over the past year, with returns of -43.84%, and has consistently underperformed against the benchmark indices, including a -52.43% drop over the last three years. Today's price summary indicates that the stock has outperformed its sector by 1.2%, but it is trading below all key moving averages, suggesting a bearish trend. The company has a very attractive valuation with a return on capital employed (ROCE) of 8.6 and is trading at a discount compared to its peers. However, the stock's performance is overshadowed by substantial operating losses, a weak ability to service debt, and a significant decline in net sales of -21.48%, leading to negative results in recent quarters.
In the broader market context, while the Sensex has gained 1.24% over the past week, Mangalam Drugs has experienced a decline of -0.61%, highlighting its underperformance relative to the market. The company's weak long-term fundamental strength, characterized by a poor EBIT to interest ratio and declining profitability, further exacerbates its challenges. Despite a rise in investor participation, as evidenced by a 282.52% increase in delivery volume, the overall sentiment remains negative due to the company's ongoing financial struggles and consistent underperformance against the benchmark over the last three years.